Generic Name: Umeclidinium and vilanterol
Instructions for use
- Wash and dry your hands well.
- Open the cover of the inhaler down until you hear a click.
- Do not shake this inhaler.
- Exhale out through mouth away from inhaler.
- Place the mouthpiece into your mouth and close your lips tightly around it.
- Inhale deeply through your mouth. Be careful not to block the air vent on the front of the inhaler with your fingers.
- Remove the mouthpiece and hold breath for at least 3-4 seconds or as long as comfortable.
- Exhale through your mouth slowly and away from the inhaler.
- You may not taste or feel the medicine, even when you are using the inhaler correctly. Do not take another dose.
- Close the inhaler.
- Store inhaler in a cool dry place.
Important note: If you open and close the inhaler without inhaling the medicine, you will lose the dose. Only open the inhaler if you are ready to take your dose.
If you have questions about the use of your inhaler, please ask your pharmacist or provider.
Key product details
Medication Class & Use
- Combination bronchodilator (long-acting beta-2 agonist (LABA) and anticholinergic): Combines two medicines that work together to relax the muscles that tighten around the airway and make breathing easier.
Use this inhaler every day to prevent symptoms, even when feeling well.
- Do not use for fast relief.
- Do not use in combination with other LABA containing medicines.
- Maintenance treatment of COPD: 1 inhalation once daily.
- Available Strengths: 62.5mcg/25mcg
- Inhaler contains 30 doses (institutional model has 7 doses.)
- Inhaler is empty when dose counter reads 0 (the counter is red for doses 9-0 to remind getting a refill.)
Discard inhaler 6 weeks after opening foil pouch (or when dose counter reads 00, whichever comes first.)
- Keep inhaler dry at all times. Use a dry cloth to gently wipe mouthpiece if needed.
- Watch for drug interactions with CYP 450 3A4 inhibitors, MAO inhibitors, tricyclic antidepressants. Do use in combination with other LABAs or anticholineric drugs.
- Do not use if patient has a severe allergy to milk proteins.
- Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. The safety and efficacy of ANORO ELLIPTA in patients with asthma have not been established. ANORO ELLIPTA is not indicated for the treatment of asthma.
- Galvin WF, Dunn PJ, Kallstrom TJ. A Patient’s Guide to Aerosol Drug Delivery. American Association for Respiratory Care; 2010.
- Product Information: ANORO ELLIPTA inhalation powder, umeclidinium and vilanterol inhalation powder. GlaxoSmithKline, Research Triangle Park, NC, 27709. 2016.
This site does not endorse or recommend any individual medication and does not accept funding or advertising from drug manufacturers. Our intent is to share information about medication use so that you get the most benefit from your medicine.
The information provided is educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment.
Copyright @2022 Fairview Physician Associates. All rights reserved.